Phase II trials of acalabrutinib in patients hospitalised with Covid-19 failed to meet primary endpoint

Acalabrutinib is a selective inhibitor of Bruton’s tyrosine kinase, recently approved for the treatment of chronic lymphocytic leukaemia. In the two CALAVI trials, acalabrutinib failed to reduce respiratory failure or death in patients with respiratory complications of Covid-19.

Source:

Biospace Inc.